Founder
Jibin Yu (Chairman and CEO)
He is a leading talent in Dongwu science and technology entrepreneurship and a leading talent in Gusu, Suzhou. He has more than 20 years of experience in R&D and management in molecular biology and genetic engineering. He is a master jointly trained by Soochow University and the Chinese Academy of Sciences.
In 2002, he joined Shanghai Bioasia Biotechnology Co., Ltd., where he established one of the earliest industrialized gene synthesis processes based on PCR amplification in China. The company was acquired by Invitrogen (now one of the sub-brands of Thermo Fisher) in 2004.
In June 2005, he joined Nanjing GenScript Biotech Corporation (H.K.01548) and was in charge of the gene synthesis business. In the same year, due to his outstanding performance, he was promoted to vice president, responsible for the company's production and R&D, including core businesses such as gene synthesis, protein engineering, antibody engineering, and new drug screening, becoming one of the core management members of the company. During his ten years in senior management, Nanjing GenScript transformed from a start-up to the world's largest PCR experimental base and gene synthesis center and successfully went public on the Hong Kong Stock Exchange in 2015. His strong innovation capabilities have made his group company and subsidiaries (Nanjing Legend Biotech, listed on NASDAQ in the United States, LEGN; Nanjing Pengbo Biotech) stars in China's biotechnology industry.
In 2016, he began to plan and establish Suzhou Xianda Gene Technology Co., Ltd. Based on his profound understanding of PCR, nucleic acid molecules, nucleic acid-acting enzymes, antibody affinity maturation, molecular directed evolution, etc. for more than ten years, he led the team to develop the nucleic acid isothermal ERA amplification technology with global independent intellectual property rights. And continuously innovating and improving on this basis, he developed the NEW ERA super-amplification technology. Combined with the developed miniature handheld fluorescence device (trade name: Gene Mirror), on-site nucleic acid detection within 10-15 minutes has been realized. Through the mobile APP software (Gene Mirror), the test results can be uploaded to the server data center in real time, and the distribution of the epidemic situation can be obtained in real time. Currently, the company's products cover the fields of rapid food safety detection, rapid detection of pathogenic bacteria in livestock, aquatic products, molecular diagnosis, and POCT. The company is a member unit of the National Health Industry Enterprise Management Association. The company completed the PreA round of financing in 2020 and will gradually build an innovation-driven technology enterprise based on rapid nucleic acid detection.
Co-Founders
Lei Zhang(Sales VP)
Graduated from Soochow University, he has more than ten years of working experience in the medical industry and focuses on promoting the practice and development of technology in hospitals. He has successively served as domestic sales manager and director in companies such as Sweden Contec, Roche Diagnostics, and general manager of Shanghai Jiuxiang Medical Company.
David Chen(Research & Development VP)
He holds a master's degree in biology from Soochow University and has nearly 20 years of experience in R&D, production, strategy, and other operations and management in biotechnology service and product R&D enterprises. He has successively served as vice president of operation and development and senior manager of the production department in two listed international biotechnology companies.
Harriet Huang(Operations VP)
She holds a master's degree in biology from Soochow University and has more than ten years of experience in R&D, registration, production, quality, and marketing operations and management in in vitro diagnostic reagent enterprises. She has experience in the full life cycle management of products and product access in multiple countries.
Jun Li (Scientific Advisor)
He is a Ph.D. in biochemistry from the University of Utah in the United States, an internationally renowned expert in biopharmaceutical R&D, a "Double Creation" talent in Jiangsu Province, and a Gusu talent in Suzhou. He is the general manager of a domestic biomedical company and has more than 20 years of experience in bioengineering and drug R&D. He once served as a senior researcher and project leader in the Novartis Institutes for BioMedical Research in the United States.